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ABSTRACT
Acne, one of the most common skin diseases,
affects approximately 85% of the adolescent
population, and occurs most prominently at
skin sites with a high density of sebaceous
glands such as the face, back, and chest.
Although often considered a disease of
teenagers, acne is occurring at an increasingly
early age. Rosacea is a chronic facial
inflammatory dermatosis characterized by
flushing (or transient facial erythema),
persistent central facial erythema, inflammatory
papules/pustules, and telangiectasia. Both acne
and rosacea have a multifactorial pathology that
is incompletely understood. Increased sebum
production, keratinocyte hyper-proliferation,
inflammation, and altered bacterial
colonization with Propionibacterium acnes are
considered to be the underlying disease
mechanisms in acne, while the multifactorial
pathology of rosacea is thought to involve both
vasoactive and neurocutaneous mechanisms.
Several advances have taken place in the past
decade in the research field of acne and rosacea,
encompassing pathogenesis and epidemiology,
as well as the development of new therapeutic
interventions. In this article, we provide an
overview of current perspectives on the
pathogenesis and treatment of acne and
rosacea, including a summary of findings from
recent landmark pathophysiology studies
considered to have important implications for
future clinical practice. The advancement of our
knowledge of the different pathways and
regulatory mechanisms underlying acne and
rosacea is thought to lead to further advances
in the therapeutic pipeline for both conditions,
ultimately providing a greater array of
treatments to address gaps in current
management practices.
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ACNE
Acne is a chronic inflammatory disease of
the pilosebaceous unit and occurs most
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prominently at skin sites with a high density of
sebaceous glands [e.g., the face (99% of cases),
back (60% of cases), and chest (15% of cases)]
[1]. Although it predominantly affects the
adolescent population (approximately 85%), it
can also affect pre- and post-adolescents. The
pathogenesis of acne is multifactorial and
polymorphic, and several different grading
systems have been developed to assess the
severity of acne. Substantial acne is associated
with social impairment, diminished quality of life,
depression, and reduced global self-esteem [2, 3].
ACNE PATHOGENESIS: NEW
HORIZONS
Several primary and secondary factors are
believed to contribute to the onset and
development of acne [4]. Specifically, the basic
disease mechanism is thought to involve
increased sebum production, keratinocyte
hyperproliferation, inflammation, and altered
bacterial colonization, primarily with
Propionibacterium acnes (Fig. 1). The exact
sequence of these events is unclear, but the
major pathophysiologic factor is likely to be
an androgen-induced increase in sebum
production and secretion, coupled with
qualitative changes in sebum. Characteristic
changes in sebum composition reported in
acne patients include reduced levels of linoleic
acid, increased levels of squalene and lipid
peroxides, and an increased ratio of
saturated/mono-unsaturated fatty acids [4–6].
Hormones, the environment, neurologic and
inflammatory mediators, and lipid metabolism
have all been implicated in the regulation of
sebum production [4].
The quantitative and qualitative changes in
sebum production have also been implicated in
colonization of the follicular duct by P. acnes.
Notably, sebum quality may influence skin
microbiome composition, particularly in terms
of the abundance and strains of P. acnes
populating the pilosebaceous unit. P. acnes is
thought to contribute to acne pathogenesis
through several different mechanisms
including interaction with innate cutaneous
immunity and keratinocyte and sebocyte
function, leading to amplification of the three
key pathologic processes implicated in acne
development: inflammation, keratinization,
and sebogenesis [7].
Support for the development of therapies
that target molecules implicated in the
activation of innate immunity is provided by
several research findings. These include a
confirmed association between sebaceous lipid
synthesis and inflammation [8] and evidence of
elevated levels of CD3? and CD4? T cells and
inflammatory markers in early subclinical acne
lesions (microcomedones) [9, 10]. Furthermore,
recent studies highlight the important
contributory role of Toll-like receptor
activation and subsequent interleukin-1 alpha
secretion by keratinocytes in comedogenesis
[10, 11].
The pilosebaceous unit and resident
sebocytes also play an active role in skin
endocrine function. Androgen hormones as
well as growth-promoting hormones and
growth factors control sebaceous gland
function, and recent attention has focused on
insulin/insulin growth factor-1 signaling and its
ability to stimulate sebocyte proliferation and
differentiation. Importantly, endocrine changes
closely related to pubertal rises in insulin
resistance have been reported to affect acne
onset and development, leading to a
re-evaluation of nutritional influences and
Fig. 1 Primary and secondary factors contributing to acne
pathogenesis
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endocrine factors involved in the promotion of
acne development [12]. The Western diet,
characterized by a high glycemic load, may be
an environmental factor linking acne to
hyperinsulinemia and may represent a
targetable adjunctive aspect of acne
pathogenesis. A low-glycemic-load diet appears
to ameliorate the signs of acne, reducing
the number of both inflammatory and
non-inflammatory lesions and affecting the
fatty acid composition of sebum triglycerides
through reduced fatty acid mono-unsaturation
[4, 12]. Consumption of milk can induce
mechanistic target of rapamycin-1 (mTORC1)
signaling through several different pathways
[13]. A major mechanism is considered to be the
stimulation of IGF-1 production by the liver
following ingestion of specific amino acids
found in milk. These include tryptophan-rich
lactalbumin, relevant for the hepatic synthesis
of IGF-1, and the branched amino acids leucine,
isoleucine, and valine, involved in the
stimulation of insulin secretion [14]. Moreover,
milk proteins possess approximately twice the
amount of glutamine as beef, and glutamine in
the sebaceous gland is required for cellular
proliferation and lipogenesis, as a large amount
is converted to the amino acids glutamate,
alanine, serine, glycine, and aspartate [15]. A
combination of these milk-derived metabolic
effects can explain the elevated insulinemic
index induced by the consumption of whole
and skimmed milk. Evidence also suggests that
peroxisome proliferator-activated receptors
(PPAR) expressed in sebaceous-gland cells and
their ligands play an important role in the
regulation of human sebum production and
acne development [8, 16, 17].
The clarification that sebum alterations and
inflammation represent the primary events in
acne pathogenesis indicates that these
phenomena should be the primary therapeutic
targets. In line with this view, systemic or
topical antibiotic therapy should be prescribed
for limited periods in patients with pustular or
nodular lesions, whereas molecules to control
sebum production and the inflammatory
process should be prescribed longer term.
FOCUS ON PEDIATRIC ACNE
The Earlier Onset of Acne
Although often considered a teenage disease,
acne is occurring at an increasingly early age,
possibly because of earlier puberty and/or other
factors. Twelve years of age is no longer
considered the low end of the ‘normal’ range
for onset, and there has been an overall decrease
in the average age of children seeking treatment
for acne. This earlier onset mirrors a downward
trend in age at the start of puberty and may
represent the first sign of pubertal onset in
children aged 7–11 years [18–20]. Acne and
acne-like conditions can also develop in
neonates, infants, and young children, and
may be associated with differential diagnoses
or systemic pathologies that differ from those of
pre-teen and teenage acne vulgaris. The American
Acne and Rosacea Society/American Academy of
Pediatrics guidelines promote recognition of early
acne, pathologic acne (acne associated with
underlying endocrinologic or other pathologic
conditions), and scarring acne [21].
Neonatal Acne
Neonatal acne develops during the first 0–6
weeks of life and is characterized by
erythematous papulopustules affecting the
face, scalp, neck, and torso. Not considered
true acne, neonatal acne may be associated with
skin colonization by Malassezia species
(M. sympodialis, M. globosa) and is usually a
self-limiting condition, although symptom
resolution may be achieved more quickly with
a topical anti-yeast cream [21, 22].
Infantile Acne
The term ’infantile acne’ is given to acne that
develops during the early months or first year of
life. Comedones are usually present, often with
papules, pustules, cysts, nodules, and scarring.
Use of topical (benzoyl peroxide, retinoids,
antibiotics) or systemic therapy (oral antibiotics
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and, in some circumstances, isotretinoin) has been
reported in the literature and some guidelines [21].
The etiology of infantile acne is thought to be
multifactorial, involving increased sebum
excretion, stimulation of sebaceous glands by
maternal or neonatal androgens, and
colonization of sebaceous glands by Malassezia
species [23].
Mid-Childhood Acne
Mid-childhood acne is very uncommon and
affects children aged 1–7 years; a diagnosis
warrants endocrinologic evaluation by a
pediatric endocrinologist for causes of
hyperandrogenism. It may be associated with
premature adrenarche, Cushing’s syndrome,
congenital adrenal hyperplasia, gonadal/
adrenal tumors, or precocious puberty. Patient
evaluation should also include assessment of
growth, bone age, and Tanner stage and
measurement of total/free testosterone,
dehydroepiandrosterone, androstenedione,
luteinizing hormone, follicle-stimulating
hormone, prolactin, and 17-hydroxyprogesterone
[21].
Pre-Adolescent Acne
Pre-adolescent acne (onset aged 7–12 years) is
common and may precede other signs of
pubertal maturation [21]. Investigation other
than a medical history and physical
examination is generally unnecessary unless
there are signs of androgen excess, polycystic
ovarian syndrome, or other systemic
abnormalities. Pre-adolescent acne is
characterized by the presence of comedones
most frequently on the forehead and mid-face
(rarely the trunk area) and an increase in sebum
production and sebaceous follicle number
[24–26].
In the US, physicians prescribe a wide variety
of medications to treat pre-adolescent acne, and
prescribing patterns vary substantially between
clinicians of different specialties [27].
Shortcomings of current treatment approaches
include over-reliance on oral antibiotics and
underuse of topical retinoids, as well as
prescribing of oral antibiotics without benzoyl
peroxide or retinoids. Furthermore, there are
‘practice gaps’ (differences between practitioner
prescribing and expert/guideline best practice
recommendations) and a general under-appreciation
of early, significant acne as a predictor of more
severe acne over time.
Adolescent Acne
Adolescent acne manifests between the ages of
12 and 18 years, and is very common.
According to the American Acne and Rosacea
Society, treatment should be selected based on
disease severity (mild, moderate, or severe) and
the psychologic impact of the disease on the
patient, including the likelihood of scarring
and/or dyspigmentation. Treatment options
include oral/topical antibiotic therapy,
oral/topical retinoids, and benzoyl peroxide
(Fig. 2) [21].
Treatment Challenges in Pediatric
and Adolescent Acne
Special considerations in the treatment of
pediatric patients with acne include previous
treatment, cost, vehicle selection, ease of use,
management of expectations and side effects,
psychosocial impact on the patient, active
scarring, and regimen complexity. In recent
years, intensive antibiotic use has contributed
to the development of antimicrobial resistance,
with the emergence of antibiotic-resistant
P. acnes and staphylococci strains becoming a
major global health concern [28]. In an effort to
address this, the new American Academy of
Dermatology and European Dermatology
Forum guidelines stipulate that systemic
antibiotic use should be limited to the shortest
possible duration, typically 3 months, and
recommend against systemic antibiotic
monotherapy [1, 21]. Furthermore, due to
limited supportive data, the use of systemic
antibiotics, other than tetracyclines and
macrolides, is not recommended [29].
Hormonal therapy, in the form of combined
oral contraceptives (COC), may be useful as
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second-line therapy for pubertal females with
moderate/severe acne [21]. If considered an
appropriate option, the patient’s tobacco use
and family history of thrombotic events should
be assessed, and initiation of COC therapy
should be delayed until at least 1 year after
onset of menstruation because of concerns
about growth and bone density. Isotretinoin is
recommended for severe, scarring, and/or
refractory acne in adolescents and may be
used in younger patients [21]; however,
extensive counseling, particularly on avoiding
pregnancy, and careful monitoring of potential
side effects and toxicities are recommended for
patients prescribed this treatment.
Given the concerns surrounding the
emergence of drug resistance among patients
with acne, drug development programs are
moving away from oral antibiotic therapies
and toward novel therapeutic approaches.
Promising avenues of research currently
include nitric oxide-based medications, drugs
that target acetyl-CoA carboxylase, sebum or
lipid synthesis mediators or inflammatory
mediators, novel retinoids, and vaccines
against P. acnes.
ROSACEA
Rosacea is a chronic facial inflammatory
dermatosis with manifold manifestations
characterized by the presence of one or more
of the following primary features: flushing (or
transient facial erythema), persistent central
facial erythema, inflammatory papules/pustules,
and telangiectasia (for comprehensive reviews
on rosacea, see [30, 31]). In addition, secondary
features may be present, including: burning/
stinging, plaque, dry appearance, edema, ocular
manifestations, peripheral location, and
phymatous changes. Rosacea can be divided
into four subtypes (erythemato-telangiectatic,
papulopustular, phymatous, and ocular), with
erythemato-telangiectatic rosacea being the
most common [32]. There is a wide range in
the estimated prevalence of rosacea (0.1–22%)
likely due to differences in case definitions. To
address this issue and to concord with case
definitions described by the National Rosacea
Society, a highly sensitive screening instrument,
Rosascreen, was developed [33]. Using this tool,
followed by dermatologist verification of cases,
Fig. 2 American Acne and Rosacea Society treatment
recommendations for mild, moderate, and severe pediatric
acne [21] (please refer to your local prescribing
information for country-specific guidance). Reproduced
with permission from Pediatrics, 131 Suppl 3, S163–6,
Copyright  2013 by the AAP. *Topical fixed-combination
prescriptions available. **Assess adherence. Consider
dermatology referral
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rosacea prevalence in Germany and Russia has
been reported at 12.3% and 5.0%, respectively
[34]. Further use of this instrument in
epidemiologic research may provide more
accurate prevalence estimates.
Although environmental factors contribute
to the development of rosacea, there is also a
strong genetic component (46%) [35]. In a
genome-wide association study, a single
nucleotide polymorphism, intergenic between
HLA-DR and BTNL2, and three HLA alleles, all
coding for MHC class II proteins, were
significantly associated with rosacea [36].
However, the phenotypic presentation of
rosacea was not stated. In addition, an
association has been established between
rosacea and several chronic systemic diseases
including gastroesophageal reflux disease,
hyperlipidemia, hypertension, metabolic
Fig. 3 Factors contributing to rosacea pathogenesis
Fig. 4 Innate and adaptive immune dysfunction in rosacea
and potential therapeutic targets. The sequence of innate
immune activation in rosacea starts with factors increasing
keratinocyte transcription of pro-cathelicidin (including
vitamin D activated by UV, UV itself, infection, injury,
and other triggers to barrier disruption) [43] and the serine
proteases of the KLK family, KLK5 and KLK7 (activation
mediated by TLR-2, which is upregulated by environmental
and microbial stimuli) [42]. This leads to the formation of
LL-37 and other peptides that are inflammatory and
angiogenic [44]. Mast cells are pivotal mediators of
cathelicidin-initiated skin inflammation—amplifying
inflammation, vasodilation, and generation of LL-37 [45].
Chemokine and cytokine signals interact to generate a
Th1/Th17-polarized adaptive immune response in rosacea
[46]. Increased amounts of serine proteases can activate TRP
via upregulation and/or activation of protease-activated
receptors. There is co-localization of mast cells with
unmyelinated sensory nerves, blood vessels, and myofibroblasts
in rosacea (not shown) [41]. Sites of potential therapeutic
intervention in these pathways are shown. KLK kallikrein,
LL-37 cathelicidin, Th1 type 1 T-helper, Th17 type 17
T-helper, TL Toll-like receptor, UV ultraviolet
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diseases, cardiovascular diseases, diabetes,
celiac disease, multiple sclerosis, rheumatoid
arthritis, and glioma [37–40]; however,
the pathophysiologic link between rosacea
and these conditions remains to be elucidated.
Optimizing Clinical Care: Application
of the Latest Research
Rosacea has a multifactorial pathology
involving vasoactive and neurocutaneous
mechanisms, as well as innate and adaptive
immunity. Each of these factors contributes to
the disease to a different extent in each
individual (Fig. 3). Over the past decade, the
management of rosacea has evolved from
empiricism to rational selection based on
disease pathogenesis. While standard
measures, including avoidance of triggers,
gentle cleansers, and moisturizers in combination
with sun protection, may mitigate flares, control
signs and symptoms in some patients, others will
require more specific therapy.
In the past, treatments for rosacea have
primarily been confined to therapies indicated
for other conditions (e.g., beta-blockers for
flushing, antibiotics for acne vulgaris).
However, more recently, treatments have been
specifically developed based on our evolving
understanding of the pathogenesis of rosacea
(Fig. 4). Currently available treatment options
based on positive outcomes from randomized
controlled trials include topical brimonidine or
intense pulsed light (IPL) for background
persistent erythema; topical metronidazole,
azelaic acid, ivermectin, or oral doxycycline
and isotretinoin for papulopustules of rosacea;
and cyclosporine eye drops for ocular rosacea
[47]. Consensus on the optimal treatment for
phymatous rosacea has yet to be reached
because of a lack of robust clinical trial data.
A useful summary of findings for all
evidence-based interventions for treating
different manifestations of rosacea is provided
in a recently published Cochrane review [48].
Although the past decade has witnessed
important advances in our understanding and
management of rosacea, it is anticipated that
the findings from recent landmark
pathophysiology studies will have important
implications for future clinical practice. For
example, gene array analyses indicate that
each rosacea subtype can be differentiated by a
selective gene profile, suggesting that the
pathomechanisms of the different subtypes
may vary with respect to the molecular
pathways involved [49]. Other promising
avenues of research include the role of
cathelicidin antimicrobial peptides in aberrant
innate immune responses [44, 50], the role of
mast cells as keymediators of cathelicidin-initiated
inflammation in rosacea [45], characterization of
inflammatory infiltrate and cytokine/chemokine
profiles, including Th1/Th17 pathway activation
[46], and elucidation of mediators and receptors
involved in neurovascular and neuroimmune
aspects of rosacea [49]. Based on these recent
basic science insights, mast-cell-stabilizing
agents, calcitonin-gene-related peptide,
substance P, and transient receptor potential
channel inhibitors may represent possible
contenders for future therapeutic strategies to
treat rosacea.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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